The market will be closely following the event, looking for updates on the prospects of the company turning profitable in the near term. Encouragingly, the management’s branding initiatives and efforts to ramp up the online platform seem to have positively influenced performance in the second half, and the trend is expected to continue in the coming months.
Growth Drivers
The roll-out of fulfillment centers and augmentation of delivery services should add to sales growth in the third quarter. Also, the market’s response to the recently launched Chewy Pharmacy has been positive. There is no doubt it is a promising venture, considering the growing awareness about pet-wellbeing.
Like in the case of all emerging start-ups, Chewy’s margins remain under pressure from high selling and administrative expenses, though its impact on the bottom line is expected to be lighter this time compared to the previous quarters.
Loss Widens
In the second quarter, sales surged 43% annually to $1.15 billion and exceeded the consensus forecast, reflecting a sharp increase in the number of active customers to 12 million. However, the company posted a wider loss of $0.21 per share that missed the estimates.
Upgrade
Chewy got a major boost Thursday after Morgan Stanley (MS) upgraded its rating on the stock to Overweight, citing favorable market conditions for the business that might help the company double its sales in the next five years.
Since the mixed Wall Street debut around six months ago, the stock declined steadily and hit an all-time low last month. The value dropped 34% so far and traded below the $25-mark this week.